Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised,... by Huang, Jing, Prof, Xu, Jianming, Prof, Chen, Yun, MD, Zhuang, Wu, MD, Zhang, Yiping, Prof, Chen, Zhendong, Prof, Chen, Jia, Prof, Zhang, Helong, Prof, Niu, Zuoxing, Prof, Fan, Qingxia, Prof, Lin, Lizhu, Prof, Gu, Kangsheng, Prof, Liu, Ying, MD, Ba, Yi, Prof, Miao, Zhanhui, MD, Jiang, Xiaodong, MD, Zeng, Ming, Prof, Chen, Jianhua, Prof, Fu, Zhichao, MD, Gan, Lu, MD, Wang, Jun, Prof, Zhan, Xianbao, Prof, Liu, Tianshu, Prof, Li, Zhiping, Prof, Shen, Lin, Prof, Shu, Yongqian, Prof, Zhang, Tao, PhD, Yang, Qing, MD, Zou, Jianjun, MD

Get full text

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-... by Wu, Xiaohua, Ji, Jiafu, Lou, Hanmei, Li, Yunxia, Bachelor, Feng, Mei, Xu, Nong, MD, Li, Yuzhi, MD, Wang, Jing, MD PHD, Huang, Yi, MD, Lou, Ge, An, Ruifang, MD, PhD, Li, Changzheng, Zhou, Qi, Prof, Huang, Xin, Zhao, Enfeng, Liu, Tianshu, Fan, Qingxia, MD, Li, Guiling, Li, Baiyong, Xia, Yu

Get full text